A case is described where systemic levels of prostacyclin metabolite were measured during inhaled aerosolized prostacyclin (IAP) therapy for severe hypoxaemia in a patient with the acute respiratory distress syndrome. Comparable levels of prostacyclin metabolite have been associated with a marked platelet aggregation defect in vitro. A platelet aggregation defect was also demonstrated in vivo in this patient. Haemodynamic and gas exchange data during the IAP therapy are described.
WetzelR.C.Aerosolized prostacyclin: In search of the ideal pulmonary vasodilator.Anesthesiology1995; 82: 1315–1317.
2.
van HeerdenP.V., WebbS.A.R., HeeG., CorkeronM., ThompsonW.R.Inhaled aerosolized prostacyclin as a selective pulmonary vasodilator for the treatment of severe hypoxaemia.Anaesth Intens Care1996; 24: 87–90.
3.
HablerO., KleenM., ZwisslerB.. Inhalation of prostacyclin (PG12) for 8 hours does not produce signs of acute pulmonary toxicity in healthy lambs.Intens Care Med1996; 22: 426–433.
4.
MurrayJ.F., MatthayM.A., LuceJ.M., FlickM.R.An expanded definition of the adult respiratory distress syndrome.Am Rev Respir Dis1988; 138: 720–723.
5.
BardenA., BeilinL.J., VandongenR., RouseI.Influence of age, sex and potassium excretion on urinary prostaglandins.Clinical Sciences1985; 68: 601–604.
6.
BurghuberO.C., SilberbauerK., HaberP., SinzingerH., ElliottM., LeithnerC.Pulmonary and antiaggregatory effects on prostacyclin after inhalation and intravenous infusion.Respiration1984; 45: 450–454.
7.
SzczeklikA., GryglewskiR.J., NizankowskaE., NizankowskiR., MusialJ.Pulmonary and anti-platelet effects of intravenous and inhaled prostacyclin in man.Prostaglandins1978; 16: 651–660.
8.
van HeerdenP.V., GibbsN.M., MichaloupolosN.The effect of low concentrations of prostacyclin on platelet function in vitro.Anaesth Intens Care1997; 25: 343–346.
